A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function
NCT01278758
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
7
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Cancer
Interventions
DRUG:
ASA404, DMXAA or DXAA
Sponsor
Novartis Pharmaceuticals